A Study of DS-9606a in Patients With Advanced Solid Tumors
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
88actual
Sites
7
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
It was Daiichi Sankyo, Inc.'s decision to discontinue further internal development of DS-9606a
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-31 | actual | When the study began enrolling |
| Primary completion | 2026-02-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-06 | actual | The whole study's end, after follow-up |
| First posted | 2022-05-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Cancer
- Metastatic Cancer
- Germ Cell Tumor
Intervention
- Drug: DS-9606a
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Dose-Limiting Toxicities (DLT) in Participants Receiving DS-9606a
measured Cycle 1 Day 1 through Day 21 of Cycle 2 (each cycle is 21 days)
Number of Participants with Treatment-emergent Adverse Events (TEAEs) in Participants Receiving DS-9606a
measured Cycle 1 Day 1 to 90 days after last dose, up to 42 months (each cycle is 21 days)
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed